A study published in the European Heart Journal found that semaglutide, a medication for type 2 diabetes, reduces major adverse cardiovascular events (MACEs) and improves metabolic outcomes compared to a placebo, regardless of baseline glycated hemoglobin (HbA1c) levels. The study analyzed data from two randomized controlled trials and included 6480 participants with type 2 diabetes and cardiovascular disease or high cardiovascular risk. Semaglutide was associated with a lower risk of MACEs and consistent reductions in HbA1c and body weight, regardless of baseline HbA1c levels. The researchers concluded that semaglutide benefits were consistent across all HbA1c levels.
Source link
Semaglutide Treatment Exhibits Cardioprotective Utility Across HbA1c Levels
